231 related articles for article (PubMed ID: 22023526)
1. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.
Boissel L; Betancur M; Lu W; Wels WS; Marino T; Van Etten RA; Klingemann H
Leuk Lymphoma; 2012 May; 53(5):958-65. PubMed ID: 22023526
[TBL] [Abstract][Full Text] [Related]
2. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.
Suerth JD; Morgan MA; Kloess S; Heckl D; Neudörfl C; Falk CS; Koehl U; Schambach A
J Mol Med (Berl); 2016 Jan; 94(1):83-93. PubMed ID: 26300042
[TBL] [Abstract][Full Text] [Related]
3. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes.
Rabinovich PM; Komarovskaya ME; Wrzesinski SH; Alderman JL; Budak-Alpdogan T; Karpikov A; Guo H; Flavell RA; Cheung NK; Weissman SM; Bahceci E
Hum Gene Ther; 2009 Jan; 20(1):51-61. PubMed ID: 19025415
[TBL] [Abstract][Full Text] [Related]
4. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.
Colamartino ABL; Lemieux W; Bifsha P; Nicoletti S; Chakravarti N; Sanz J; Roméro H; Selleri S; Béland K; Guiot M; Tremblay-Laganière C; Dicaire R; Barreiro L; Lee DA; Verhoeyen E; Haddad E
Front Immunol; 2019; 10():2873. PubMed ID: 31921138
[TBL] [Abstract][Full Text] [Related]
5. Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.
Sauerer T; Albrecht L; Sievers NM; Gerer KF; Hoyer S; Dörrie J; Schaft N
Methods Mol Biol; 2024; 2786():219-235. PubMed ID: 38814397
[TBL] [Abstract][Full Text] [Related]
6. A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.
Bari R; Granzin M; Tsang KS; Roy A; Krueger W; Orentas R; Schneider D; Pfeifer R; Moeker N; Verhoeyen E; Dropulic B; Leung W
Front Immunol; 2019; 10():2001. PubMed ID: 31507603
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.
Bari R; Granzin M; Tsang KS; Roy A; Krueger W; Orentas R; Schneider D; Pfeifer R; Moeker N; Verhoeyen E; Dropulic B; Leung W
Front Immunol; 2019; 10():2784. PubMed ID: 31839796
[TBL] [Abstract][Full Text] [Related]
8. Medicine from modified mRNA.
Johnson R
Nat Chem Biol; 2023 Dec; 19(12):1443. PubMed ID: 37989915
[No Abstract] [Full Text] [Related]
9. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.
Boissel L; Betancur-Boissel M; Lu W; Krause DS; Van Etten RA; Wels WS; Klingemann H
Oncoimmunology; 2013 Oct; 2(10):e26527. PubMed ID: 24404423
[TBL] [Abstract][Full Text] [Related]
10. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
Sahm C; Schönfeld K; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
12. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Gong JH; Maki G; Klingemann HG
Leukemia; 1994 Apr; 8(4):652-8. PubMed ID: 8152260
[TBL] [Abstract][Full Text] [Related]
14. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
[TBL] [Abstract][Full Text] [Related]
15. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
16. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
17. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
Romanski A; Uherek C; Bug G; Seifried E; Klingemann H; Wels WS; Ottmann OG; Tonn T
J Cell Mol Med; 2016 Jul; 20(7):1287-94. PubMed ID: 27008316
[TBL] [Abstract][Full Text] [Related]
18. Advantages and applications of CAR-expressing natural killer cells.
Glienke W; Esser R; Priesner C; Suerth JD; Schambach A; Wels WS; Grez M; Kloess S; Arseniev L; Koehl U
Front Pharmacol; 2015; 6():21. PubMed ID: 25729364
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
